Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-02T23:56:12.030Z Has data issue: false hasContentIssue false
  • English
  • Français

Cancer survival extension from drug treatments

Published online by Cambridge University Press:  07 August 2013

Nicola Oliver  and
Helen Chung
Nicola Oliver*
Affiliation:
Swiss Re Services Ltd, London
Helen Chung
Affiliation:
Swiss Re Services Ltd, London
*
*Correspondence to: Nicola Oliver, Research Consultant, Swiss Re Services Ltd (London), 30 St Mary Axe, EC3A 8EP London, United Kingdom, Tel: +442079333730, Fax: +4479335217; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Cancer causes one in four of all deaths in the UK. Advances in biologic and pharmaceutical therapies over recent years have increased achievable survival gain in most life-limiting cancers, ranging from modest incremental improvements to step changes in life expectancy. The realised and anticipated impact of treatment advances on survival is of wide-ranging interest, from informing decisions about healthcare to understanding influences on mortality trends. This paper presents an overview of evidence for survival extension from a range of therapies that have become available in recent years for the treatment of lung, colorectal and breast cancer. The evidence considered includes short-term empirical evidence from clinical trials as well as longer-term estimates from models extrapolating over a lifetime horizon. The core data source is the evidence base supporting guidance published by the National Institute for Health and Care Excellence (NICE), UK. This evidence has already been subject to appraisal by NICE; the aim of this paper is to collate the existing estimates submitted to NICE in order to appreciate the wide range in survival extension resulting from systematically identified cancer treatments.

Keywords

cancersurvivalmortalityindividualized riskhealth technology assessment (HTA)comparative effectiveness research (CER)
Type
Sessional meetings: papers and abstracts of discussions
Information
British Actuarial Journal , Volume 18 , Issue 2 , July 2013 , pp. 467 - 485
Copyright
Copyright © Institute and Faculty of Actuaries 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albain, K., Nag, S., Calderillo-Ruiz, G., Jordaan, J., Llombart, A., Pluzanska, A. (2004). Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Journal of Clinical Oncology, 22(14), 5S.CrossRefGoogle Scholar
ATAC Trialists Group. (2004). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. The Lancet, 65, 60–62.Google Scholar
The Breast International Group (BIG) 1-98 Collaborative Group. (2006). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine, 353, 2747–2757.Google Scholar
Cancer Research UK (2011). http://info.cancerresearchuk.org/cancerstats/ accessed 1st – 9th August 2011.Google Scholar
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J., Krzakowski, M., Laack, E., Wu, Y., Bover, I., Begbie, S., Tzekova, V., Cucevic, B., Pereira, J., Yang, S., Madhavan, J., Sugarman, K., Peterson, P., John, W., Krejcy, K., Belani, C. (2009). Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet, 374, 1432–1440.CrossRefGoogle ScholarPubMed
Coombes, R., Hall, E., Gibson, L., Paridaens, R., Jassem, J., Delozier, T., Jones, S., Alvarez, I., Bertelli, G., Ortmann, O., Coates, A., Bajetta, E., Dodwell, D., Coleman, R., Fallowfield, L., Mickiewicz, E., Andersen, J., Lonning, P., Cocconi, G., Stewart, A., Stuart, N., Snowdon, C., Carpentieri, M., Massimini, G., Bliss, J., for the Intergroup Exemestane Study. (2004). The Intergroup Exemestane Study: a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350, 1081–1092.Google Scholar
EMA (2011). http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000091.jsp&murl=menus/about_us/about_us.jsp&mid=WC0b01ac0580028a42 [Accessed 1st – 9th August 2011].Google Scholar
Treasury, H.M. (2011). THE GREEN BOOK Appraisal and Evaluation in Central Government, London, TSO.Google Scholar
Hind, D., Ward, S., De Nigris, E., Simpson, E., Carroll, C., Wyld, L. (2007). Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technology Assessment, 11, 26.Google Scholar
Kaitin, K. (2010). Deconstructing the Drug Development Process: The New Face of Innovation. Clinical Pharmacology, 87, 356–361.Google Scholar
Loveman, E., Jones, J., Hartwell, D., Bird, A., Harris, P., Welch, K., Clegg, A. (2010). The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technology Assessment, 14, 19.CrossRefGoogle ScholarPubMed
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., Guevin, R., Howell, A., Fornander, T., Hainsworth, J., Coleman, R., Vinholes, J., Modiano, M., Pinter, T., Tang, S., Colwell, B., Prady, C., Provencher, L., Walde, D., Rodriguez-Lescure, A., Hugh, J., Loret, C., Rupin, M., Blitz, S., Jacobs, P., Murawsky, M., Riva, A., Vogel, C. (2005). Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine, 352, 2302–2313.Google Scholar
Meads, C., Round, J., Tubeuf, S., Moore, D., Pennant, M., Bayliss, S., McCabe, C. (2008). Evidence Review Group Report commissioned by the NHS R&D Programme on behalf of NICE Cetuximab for the first-line treatment of metastatic colorectal cancer July 2008.Google Scholar
MHRA (2012). Marketing authorizations: http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Marketingauthorisations/index.htm [Accessed 10 April 2012].Google Scholar
Mok, T., Wu, Y.L., Thongprasert, S., Yang, C.H., Chu, D.T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J.J., Chewaskulyong, B., Jiang, H., Duffield, E., Watkins, C., Armour, A., Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361, 947–957.Google Scholar
NICE (2005). Technology Appraisal No. 93, August 2005, ‘Colorectal cancer advanced – irinotecan, oxaliplatin and raltitrexed’.Google Scholar
NICE (2006a). Technology Appraisal No. 100, April 2006, ‘Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes C) colon cancer’.CrossRefGoogle Scholar
NICE (2006b). Technology Appraisal No. 107, August 2006, ‘Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer’.Google Scholar
NICE (2006c). Single Technology Appraisal for Achieving Clinical Excellence In The Adjuvant Treatment Of Her-2 Positive Breast Cancer – Herceptin (trastuzumab) For the Adjuvant Treatment of HER-2 Positive Breast Cancer (Submission by Roche).Google Scholar
NICE (2006d). Technology Appraisal No. 109, September 2006, ‘Docetaxel for the adjuvant treatment of early node-positive breast cancer’.Google Scholar
NICE (2006e). Technology Appraisal No. 112, November 2006, ‘Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer’.Google Scholar
NICE (2006f). Single Technology Appraisal Submission To The National Institute For Health And Clinical Excellence – Gemcitabine for the treatment of metastatic breast cancer (Submission by Eli Lilly and Company) May 2006.Google Scholar
NICE (2007). Technology Appraisal No. 116, January 2007, ‘Gemcitabine for the treatment of metastatic breast cancer’.Google Scholar
NICE (2008a). Technology Appraisal No. 162, November 2008, ‘Erlotinib for the treatment of non-small-cell lung cancer’.Google Scholar
NICE (2008b). Single Technology Appraisal for Pemetrexed for the first-line treatment of non-small cell lung cancer (Submission by Eli Lilly and Company) December 2008.Google Scholar
NICE (2008c). Guide to the Methods of Technology Appraisal June 2008.Google Scholar
NICE (2009a). Technology Appraisal No. 181, September 2009, ‘Pemetrexed for the first-line treatment of non-small-cell lung cancer’.Google Scholar
NICE (2009b). Single Technology Appraisal for Pemetrexed in the maintenance treatment of advanced non-small cell lung cancer (Submission by Eli Lilly and Company) August 2009.Google Scholar
NICE (2009c). Technology Appraisal No. 184, November 2009, ‘Topotecan for the treatment of relapsed small-cell lung cancer’.Google Scholar
NICE (2009d). Technology Appraisal No. 176, August 2009, ‘Cetuximab for the first-line treatment of metastatic colorectal cancer’.Google Scholar
NICE (2010a). Technology Appraisal No. 190, June 2010, ‘Pemetrexed for the treatment of non-small-cell lung cancer’.Google Scholar
NICE (2010b). Technology Appraisal No. 192, July 2010, ‘Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer’.Google Scholar
NICE (2010c). Single Technology Appraisal for Gefitinib for the first line treatment of locally advanced or metastatic non-small lung cancer (Submission by Astra Zeneca UK Ltd.).Google Scholar
NICE (2011). Clinical Guideline No. 131, November 2011 ‘Colorectal cancer: The diagnosis and management of colorectal cancer’.Google Scholar
NICE (2012a). About NICE: http://www.nice.org.uk/aboutnice/whoweare/who_we_are.jsp [Accessed 18 February 2012].Google Scholar
NICE (2012b). About Technology Appraisals: http://www.nice.org.uk/aboutnice/whatwedo/abouttechnologyappraisals/about_technology_appraisals.jsp [Accessed 18 February 2012].Google Scholar
O'Brien, M., Ciuleanu, T., Tsekov, H., Shparyk, Y., Cucevia, B., Juhasz, G., Thatcher, N., Ross, G., Dane, G., Crofts, T. (2006). Phase III Trial Comparing Supportive Care Alone with Supportive Care with Oral Topotecan in Patients with Relapsed Small-Cell Lung Cancer. Journal of Clinical Oncology, 24, 5441–5447.CrossRefGoogle ScholarPubMed
Scagliotti, G.V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., Lee, J.S., Mellemgaard, A., Park, K., Patil, S., Rolski, J., Goksel, T., deMarinis, F., Simms, L., Sugarman, K.P., Gandara, D. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26, 3543–3551.Google Scholar
Schmoll, H., Tabernero, J., Nowacki, M. (2005). Safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) versus bolus 5-FU/LV as adjuvant therapy for patients with stage III colon cancer. Abstract 3523, presented at ASCO 2005.Google Scholar
The School of Health and Related Research (ScHARR). (2005). Technology Assessment Report commissioned by the NHS R&D HTA Programme on behalf of the National Institute for Health and Clinical Excellence – Assessment Report Guide ‘The use of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer’.Google Scholar
Shepherd, F., Pereira, J., Ciuleanu, T., Tan, E., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., van Kooten, M., Dediu, M., Findlay, B., Tu, D., Johnston, D., Bezjak, A., Clark, G., Santabárbara, P., Seymour, L. (2005). Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine, 353, 123–132.CrossRefGoogle ScholarPubMed
Smith, I., Procter, M., Gelber, R., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., Kaufmann, M., Cameron, D., Bell, R., Bergh, J., Coleman, R., Wardley, A., Harbeck, N., Lopez, L., Mallmann, P., Gelmon, K., Wilcken, N., Wist, E., Sánchez Rovira, P., Piccart-Gebhart, M. (2007). 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet, 369, 29–36.CrossRefGoogle ScholarPubMed
Trowman, R., Chung, H., Longson, C., Littlejohns, P., Clark, P. (2011). The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales. Clinical Cancer Research, 17(15), 4930–4935.CrossRefGoogle ScholarPubMed
Van Cutsem, E., Nowack, M., Lang, I., Cascinu, S., Shchepotin, I., Maurel, J., Rougier, P., Cunningham, D., Nippgen, J., Köhne, C. (2007). Randomised phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part 125(18S), 4000.Google Scholar
Woods, L., Rachet, B., Cooper, N., Coleman, M. (2007). Predicted trends in long-term breast cancer survival in England and Wales. British Journal of Cancer, 96, 1135–1138.CrossRefGoogle ScholarPubMed